Novo Nordisk and Eli Lilly Sued Over Vision Loss Risks
Patients have filed lawsuits alleging a link between GLP-1 drugs and a rare condition causing vision loss.
Updated on Sept. 19, 2026 in Diabetes
Patients have initiated legal action against pharmaceutical companies Novo Nordisk and Eli Lilly. The lawsuits center on allegations that GLP-1 medications are associated with an increased risk of a rare condition known as NAION.
Why it matters
The litigation highlights growing concerns regarding the safety profiles of widely used GLP-1 drugs. These claims come as regulatory bodies worldwide have begun mandating that manufacturers include specific warnings about potential vision loss on medication labels.
Plaintiffs filed these complaints regarding NAION, a rare condition causing vision loss, following reports of patients experiencing ocular side effects. The extent of the potential clinical impact remains under investigation by medical authorities.
The players
Novo Nordisk
This global pharmaceutical company is a major manufacturer of GLP-1 receptor agonist medications used for diabetes and weight management.
Eli Lilly
This corporation is a leading pharmaceutical developer known for producing injectable treatments for metabolic conditions.
The details
Plaintiffs contend that the manufacturers failed to adequately warn users about the risk of non-arteritic anterior ischemic optic neuropathy (NAION) linked to their drugs. In response to these reports, regulatory agencies in various nations have formally compelled both Novo Nordisk and Eli Lilly to update their product labels with warnings regarding vision loss.
Timeline
September 19, 2026: Lawsuits were identified following global regulatory updates.
The Big Picture
The global mandate for label updates follows a pattern of regulatory intervention similar to established medical surveillance and public communication protocols used during the 2003 SARS response protocols. This shift reflects a broader trend of increased post-market scrutiny for high-profile pharmaceuticals.
Patients currently prescribed GLP-1 medications should monitor their vision closely and consult with their healthcare providers regarding any sudden changes. Regulatory label updates now serve as a primary resource for identifying recognized risks associated with these treatments.
The takeaway
Patients who use these medications should remain vigilant about ocular health and consult medical professionals if they experience new symptoms. Monitoring updated medication labels is a necessary step for those managing health conditions with these specific treatments.
Further reading
Learn more about the latest updates in this field at the Diabetes section.
